Apollo Healthcare Corp. Reports Fourth Quarter of 2020 Results

Rhea-AI Summary

Apollo Healthcare Corp. (TSX: AHC, OTC QX: AHCCF) has announced financial results for Q4 and the year ended December 31, 2020. Q4 revenues reached $87.2 million, marking a significant increase from $41.8 million in Q4 2019. Year-to-date revenues totaled $321.7 million, up from $167.1 million in 2019. EBITDA for Q4 was $25.2 million, compared to a loss of $1.7 million in 2019. The company has eliminated all debt and has access to a $50 million liquidity facility. Further detailed results are available in the MD&A filed on SEDAR.

Positive

• Q4 2020 revenues reached $87.2 million, up from $41.8 million in Q4 2019.
• Year-to-date revenue increased to $321.7 million from $167.1 million in 2019.
• Q4 2020 EBITDA improved to $25.2 million from a loss of $1.7 million in Q4 2019.
• The company retired all debt during 2020.

Negative

• None.

Apollo Healthcare Corp. (formerly Acasta Enterprises Inc.) (TSX: AHC, OTC QX: AHCCF) (“Apollo” or the “Company”) today announced financial results for the quarter and year ended December 31, 2020.

The Company’s audited consolidated financial statements for the three months and year ended December 31, 2020, as well as its accompanying management discussion and analysis (MD&A) have been filed on SEDAR. Copies of the filings may be obtained at www.sedar.com. All values in this news release and the Company’s financial disclosures are in Canadian dollars unless otherwise stated.

Financial Highlights

• Revenues for the fourth quarter of 2020 were $87.2 million and $321.7 million year to date compared with $41.8 million and $167.1 million in the comparative 2019 periods. The higher revenue is the result of higher volumes sold of the Company’s products.
• EBITDA for the fourth quarter of 2020 was $25.2 million and $94.8 million year to date compared with EBITDA of negative $1.7 million and $11.3 million in the comparative 2019 periods. The improved results reflect higher volumes sold of the Company’s products.
• Adjusted EBITDA for the fourth quarter of 2020 was $26.2 million and $91.2 million year to date compared with adjusted EBITDA of negative $0.9 million and $9.6 million in the comparative 2019 periods. Adjusted EBITDA removes the effects of foreign exchange, changes in fair value of financial instruments and impairment charges.
• The Company retired all debt during year ended December 31, 2020. The Company has access to a $50 million revolver from its commercial bank should it require additional liquidity.

Please refer to Apollo’s MD&A for additional detail and discussion on the Company’s results from operations.

Advisories:

Cautionary Note Concerning Forward Looking Statements

This news release includes forward looking statements. All such statements constitute forward looking information within the meaning of applicable securities law and are made pursuant to the “safe harbour” provisions of applicable securities laws. Forward looking statements include, but are not limited to statements about other anticipated future events or results, including comments with respect to Company’s future financial performance and condition. Forward looking statements are statements that are predictive in nature, depend upon or refer to future events or conditions and are identified by words such as “will”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates” or similar expressions concerning matters that are not historical facts. Such statements are based on current expectations of the Company’s management and inherently involve numerous risks and uncertainties, known and unknown, including economic factors. The forward-looking information contained in this news release is presented for the purpose of assisting readers in understanding the Company’s business and strategic priorities and objectives. A number of risks, uncertainties and other factors may cause actual outcomes or financial results to differ materially from the forward looking statements contained in this news release, including, among other factors, those referenced in the section entitled “Risk Factors” in the Company’s annual information form for the year ended December 31, 2020, a copy of which is available on the SEDAR website at www.sedar.com under the Company’s profile. Forward looking statements contained in this news release are not guarantees of future outcomes performance and, while forward looking statements are based on certain assumptions that the Company considers reasonable, actual events could differ materially from those expressed or implied by forward looking statements made by the Company. Readers are cautioned to consider these and other factors carefully when making decisions with respect to the Company and to not place undue reliance on forward looking statements. Circumstances affecting the Company may change rapidly. Except as may be expressly required by applicable law, the Company does not undertake any obligation to update publicly or revise any such forward looking statements, whether as a result of new information, future events or otherwise. These cautionary statements expressly qualify all forward looking statements in this new release. In addition, past results are in part, reflective of the unique environment that existed during the past fiscal year and is no guarantee of future financial performance.

Non-IFRS Financial Performance Measures (Unaudited)

Adjusted net income (loss), EBITDA and adjusted EBITDA are not recognized measures under IFRS and this data may not be comparable to data presented by other companies.

Adjusted net income (loss) is calculated by adjusting net income (loss) as recorded in the unaudited condensed consolidated interim statements of income (loss) and comprehensive income (loss) for the exclusion of certain other income and expense items determined in accordance with IFRS. The Company believes that this generally accepted measure allows the evaluation of the results of continuing operations and is useful in making comparisons between periods. Adjusted net income (loss) is intended to provide investors with information about the Company’s continuing income generating capabilities. Management uses this measure to monitor and plan for the operating performance of the Company in conjunction with other data prepared in accordance with IFRS.

EBITDA is calculated by adjusting net income (loss) as recorded in the unaudited condensed consolidated interim statements of income (loss) and comprehensive income (loss) for finance costs, current and deferred income tax, depreciation and amortization expenses. The Company believes that this measure allows the evaluation of the results of continuing operations and is useful in making comparisons between periods. EBITDA is intended to provide investors with information about the Company’s continuing income generating capabilities. Management uses this measure to monitor and plan for the operating performance of the Company in conjunction with other data prepared in accordance with IFRS.

Adjusted EBITDA is calculated by adjusting net income (loss) as recorded in the unaudited condensed consolidated interim statements of income (loss) and comprehensive income (loss) for the exclusion of certain other income and expense items determined in accordance with IFRS, being the calculation for adjusted net income (loss) and then further adjusting for finance costs, current and deferred income tax, depreciation and amortization expenses. The Company believes that this generally accepted measure allows the evaluation of the results of continuing operations and is useful in making comparisons between periods. Adjusted EBITDA is intended to provide investors with information about the Company’s continuing income generating capabilities. Management uses this measure to monitor and plan for the operating performance of the Company in conjunction with other data prepared in accordance with IFRS.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005811/en/

FAQ

What were Apollo Healthcare's Q4 2020 revenues?

Apollo Healthcare's Q4 2020 revenues were $87.2 million.

How did Apollo Healthcare's EBITDA change in Q4 2020?

Apollo Healthcare's EBITDA for Q4 2020 was $25.2 million, compared to a loss of $1.7 million in Q4 2019.

What is Apollo Healthcare's year-to-date revenue for 2020?

Apollo Healthcare's year-to-date revenue for 2020 was $321.7 million.

Did Apollo Healthcare have any debt at the end of 2020?

No, Apollo Healthcare retired all its debt during the year ended December 31, 2020.

What liquidity options does Apollo Healthcare have?

Apollo Healthcare has access to a $50 million revolver from its commercial bank.